Evidence map›Paper›PMID 38956509›Full record

ArticleBMC psychiatry2024

Relationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia.

Xiaoying Wang, Wenjin Chen, Mengzhuang Gou, Wei Li, Na Li, Jinghui Tong, Yanfang Zhou, Ting Xie, Ting Yu, Wei Feng and 12 more

Abstract read
In one paragraph

Article in BMC psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xiaoying WangPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Wenjin ChenPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Mengzhuang GouPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Wei LiPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Na LiPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Jinghui TongPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Yanfang ZhouPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Ting XiePeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Ting YuPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Wei FengPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Yanli LiPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Song ChenPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Baopeng TianPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Shuping TanPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Zhiren WangPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Shujuan PanPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Xingguang LuoDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Ping ZhangPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Junchao HuangPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Li TianDepartment of Physiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Chiang-Shan R LiDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Yunlong TanPeking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China. yltan21@126.com.ORCID 0009-0009-6450-9408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreasing evidence suggested that immune abnormalities involved in the pathophysiology of schizophrenia. However, the relationship between immunity and clinical features has not been clarified. The aim of this study was to measure the plasma levels of tumor necrosis factor alpha (TNF-α) and soluble TNF-α receptor 1 (sTNF-α R1) and to investigate their association with agitation in first episode patients with schizophrenia (FEPS).

methodsThe plasma TNF-α and sTNF-α R1 levels were measured using sandwich enzyme-linked immunosorbent assay (ELISA) in the FEPS with (n = 36) and without agitation (n = 49) symptoms, and healthy controls (HCs, n = 54). The psychopathology was assessed by the Positive and Negative Syndrome Scale (PANSS), and the agitation symptoms were evaluated by the PANSS excitatory component (PANSS-EC).

resultsThe plasma TNF-α levels in patients with and without agitation symptoms were significantly higher than those in HCs. The patients with agitation had significantly higher plasma TNF-α levels compared to the patients without agitation. There were no significant differences in the sTNF-α R1 levels among the three groups. Furthermore, the plasma TNF-α levels were positively correlated with the PANSS total score, Positive and General psychopathological subscores, and PANSS-EC score in the FEPS, but the relationships were not found for the plasma sTNF-α R1 levels.

conclusionsThese results suggested that TNF-α might play an important role in the onset and development of agitation symptoms of schizophrenia.

Indexed as

Psychomotor AgitationReceptors, Tumor Necrosis Factor, Type ISchizophreniaTumor Necrosis Factor-alphaAdultFemaleHumansMalePsychiatric Status Rating ScalesYoung AdultReceptors, Tumor Necrosis Factor, Type ITumor Necrosis Factor-alphaAgitationSchizophreniaTNF-α PANSS-EC

Identifiers

PMID38956509
PMCPMC11218378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.